OAM
NDRA icon

Oxford Asset Management’s ENDRA Life Sciences NDRA Stock Holding History

Oxford Asset Management’s Portfolio NDRA Stock Details NDRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2
Closed -$94K – 1873
2018
Q4 		$94K Buy
+2
New +$231K ﹤0.01% 1653

Other funds holding NDRA

IAM
ICM Asset Management Spokane, Washington $18.1M AUM 30.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
WEC
Winslow Evans & Crocker Boston, Massachusetts $528M AUM 30.99% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oxford Asset Management's NDRA Position: Q1 2019 in Review

Oxford Asset Management sold out of ENDRA Life Sciences (NDRA) in Q1 2019, closing a stake of 2 shares — an estimated $94K sold.

Oxford Asset Management first reported a position in NDRA in Q4 2018 and held it in 1 quarter. The position peaked at $94K in Q4 2018. 9 funds tracked by Wall St. Rank hold NDRA as of Q1 2019.

  • Oxford Asset Management reported no remaining ENDRA Life Sciences position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 2 ENDRA Life Sciences shares in Q1 2019, an estimated $94K.
  • Oxford Asset Management first reported a position in ENDRA Life Sciences in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's ENDRA Life Sciences position peaked at $94K in Q4 2018.
  • 9 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.